The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era.
Johansen
K L
KL
D045930:Anabolic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001823:Body Composition; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D009277:Nandrolone / Q000494:pharmacology / Q000627:therapeutic use*; D005082:Physical Exertion / Q000502:physiology; D006435:Renal Dialysis
D045930:Anabolic Agents; D004921:Erythropoietin; D009277:Nandrolone